Figure 7.
Schematic showing how ICAM‐1 activated by platelets increases endothelial permeability after insufficient RFA. ICAM‐1 in TAECs after insufficient RFA induces platelet aggregation and activation, increases endothelial permeability through Ezrin/VE‐cadherin, and facilitates tumor transendothelial migration. R300 is used for platelet deletion and anti‐ICAM‐1 antibody is used for blockade of ICAM‐1 for potential therapy.